Skip to content
ESMO Congress 2026Developing

DESTINY-BREAST11

7 reports2 sourcesupdated 14 hours ago

Start here

Report excerpt

Liangyihui compiles seven rapid oral reports on breast cancer ADCs from ESMO 2026, covering neoadjuvant treatment in HER2-positive early breast cancer, overall survival in metastatic TNBC, sequential strategies after ADC resistance, and clinical data on ADCs with novel targets.

Excerpted from mp.weixin.qq.com

Coverage timeline

Follow the coverage to see the different angles.

Oct 23
  1. x.com
  2. mp.weixin.qq.comPick
    ESMO 2026 Breast Cancer ADC Rapid Orals Cover Neoadjuvant Therapy, Overall Survival and Resistance Sequencing

    Liangyihui compiles seven rapid oral reports on breast cancer ADCs from ESMO 2026, covering neoadjuvant treatment in HER2-positive early breast cancer, overall survival in metastatic TNBC, sequential strategies after ADC resistance, and clinical data on ADCs with novel targets.

  3. mp.weixin.qq.com
Oct 14
  1. weixin.sogou.comPick
    DESTINY-Breast11 RCB Analysis Shows T-DXd-THP Cuts Residual Burden in High-Risk HER2-Positive Early Breast Cancer

    In the phase 3 DESTINY-Breast11 trial in high-risk HER2-positive early breast cancer, neoadjuvant T-DXd followed by paclitaxel, trastuzumab and pertuzumab (T-DXd-THP) achieved a pCR rate of 67.3% versus 56.3% with dose-dense doxorubicin-cyclophosphamide followed by THP, and a prespecified RCB analysis presented at ESMO BC 2026 showed an RCB-0+I rate of 81.3% versus 69.1%. The RCB index distribution shifted toward lower residual burden (Q3/Q4 boundary 1.01 vs 1.38, P=0.0059), and among patients not reaching pCR the median RCB was 1.5 versus 1.7. The findings add pathologic-response detail beyond the binary pCR endpoint to guide postoperative adjuvant decisions in an anthracycline-free regimen.

Heat trend for this story

Heat now 20·Peak in the comparable set 37 (Oct 24 00:00)·Change over 24h in the comparable set -24%·Participants now 5

Participants counted5
0246
Heat over time
010203040Oct23Oct24Oct24Oct25

Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org